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tool enables personalising therapy by analysing discordance in hormone receptor 
(HR) and Human Epidermal Growth Factor Receptor 2 (HER2) expression in CTCs 
compared to solid tumors in metastatic breast cancer patients. It is estimated that in 
total 4,41% of metastatic breast cancer patients could be treated in a more efficient 
way, leading to increase in progression free survival of 5,59 months. Increase in clini-
cal utility is expected to be the most important consequence of this implementation 
option. ConClusions: CTCtrap as a monitoring tool is expected to be of most 
value. In this stage, a more appropropiate prescription of expensive therapies can 
be administered to patients who are sensitive for these therapies.
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objeCtives: The implementation of the 2011 German health care reform (AMNOG) 
introduced pricing mechanisms which oblige newly launched patented drugs to 
undergo an early evaluation of their additional benefit by IQWiG, with a final resolu-
tion given by the G-BA. Medicines which demonstrate an incremental therapeutic 
benefit versus an appropriate therapeutic comparator – with an innovation score 
ranging from 1 to 4 – enter the preferable pricing negotiation system; those failing 
to prove benefit – a score of 5 or 6 – are relegated to the reference pricing system. 
The study aims to discern how oncology drugs, which began the process of benefit 
assessment during 2012, fared under the new system, and whether survival data 
influenced the decisions. Methods: We reviewed both IQWiG and G-BA documents 
relating to eight cancer drugs assessed during 2012 to determine whether each drug 
received a positive or negative early benefit assessment. Reasons for each specific 
decision were then investigated. Results: Of the five drugs qualifying for pricing 
negotiations, vemurafenib (Roche, Switzerland) was the only drug to demonstrate 
a statistically significant improvement in overall survival (OS) at the time of assess-
ment. It received the highest innovation score of the five qualifying drugs. For the 
three drugs not qualifying for pricing negotiations, the G-BA cited an incomplete 
dossier or issues with comparators as the reason for rejection. ConClusions: 
Although OS is considered the favoured clinical endpoint, the study results show 
that this endpoint is not always necessary to enter pricing negotiations. However, 
when OS is not proven, the G-BA often gave a positive assessment to only a small 
portion of eligible patients. Additionally, two of the qualifying drugs were orphan 
drugs, which entails exemption from the need to prove an additional benefit if 
annual sales are below EUR50 million.
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objeCtives: Stratification of oncology drug therapy by genetic marker diagnostics 
can reveal additional patient benefit but also might influence the development 
process of drug manufacturers. The objective of this study is to identify and describe 
the most important incentives for pharmaceutical companies to develop person-
alized medicine drugs. Methods: To describe the main factors influencing the 
decision-making process in the development of personalized medicine drugs. The 
main factors influencing the process and their priority ranking were determined by 
structured expert interviews with pharmaceutical companies, test manufacturers 
and other key stakeholders such as regulatory bodies, reimbursement decision mak-
ers and payers. Results: In contrast to small companies big international compa-
nies constantly look for suitable companion diagnostic tests to select subgroups of 
high responder. The most important key factor for market success is the extent of 
clinical efficacy in comparison with competitors respectively the current treatment 
standard. Stratification of patient populations according to treatment response or 
frequency of adverse events using biomarker is regarded to increase clinical efficacy 
of the target indication. The test performance is important due to unsolved safety 
issues although not regarded as crucial for the success of the drug. In contrast 
to other stakeholders pharmaceutical companies did not consider personalized 
medicine to relevantly decrease development costs or marketing efforts respectively 
to increase the price potential for new drugs. A low prevalence of the remaining 
patient population after testing is not seen as a factor which might lead to a stop 
of the development of a new drug by pharmaceutical companies. ConClusions: 
Genetic stratification is seen as a breakthrough in cancer therapy by pharmaceutical 
companies and physicians. Due to the current need for improvement of approval 
and reimbursement processes for personalized medicine approaches in oncology 
especially in Europe future sales are more difficult to predict.
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objeCtives: HTA bodies treat end of life (EOL) conditions differently than other 
conditions? And if so does this depend on whether they have a specific policy for 
EOL? Methods: NICE’s website was searched for single technology appraisals of 
cancer drugs evaluated between January 2009 to May 2013 for which NICE’s supple-
mentary advice for EOL treatments was accepted. The websites of other agencies – 
SMC (Scotland), TLV (Sweden), PBAC (Australia), pCODR (Canada, except Quebec) and 
INESSS (Quebec) – were searched for HTAs of the drugs deemed to have met NICE’s 
EOL criteria. A literature search was performed to identify estimated willingness-
to-pay ICER threshold values (WTP-ICER) for each agency and to determine if the 
agency has a specific EOL policy. These were compared against the final ICERs of 
the retained HTAs. Results: Seventeen drugs were identified for which NICE’s 
EOL supplementary advice was accepted. Several of these were also evaluated by 
other agencies, but only those with final ICERs below the WTP-ICER were retained: 
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objeCtives: To assess the burden of hospitalization in advanced lung cancer 
patients in the United States. Methods: Oncologists (N= 101) actively involved in 
management of advanced lung cancer in United States were invited to participate 
in a lung cancer disease specific program. Each consenting physician was asked to 
complete patient record forms for 12 advanced (stage IIIB/IV) lung cancer patients 
seen in their practice and receiving 1st, 2nd or 3rd line of therapy for advanced lung 
cancer. The study period extended from Oct- Dec 2011. Data on hospitalization that 
included reasons of hospitalization and the length of stay (LOS) over the past year 
was provided by physicians from patient records. Results: Majority of the patients 
(N= 1200) were male (56%), Caucasian (71%) and Stage IV (78%), with an average age 
of 65 years. Hospitalization records were obtained for 93% (n= 1110) of the patients 
among which 22% (n= 248) of the patients ≥ 1 hospitalization events in the previ-
ous year with an average (SD) LOS of 4 (2.4) days and a median LOS of 3 days. The 
reasons reported for the 293 hospitalization events were disease symptoms (61%), 
surgery (19%) and therapy side effects (43%). The LOS for surgery related hospitaliza-
tion (n= 57) ranged from 1-12 days (mean (SD): 6 (2.9) days; median: 5 days). Among 
disease symptoms reported as reasons for hospitalization, the most frequent were 
pain (51%), dyspnea (47%) and cough (47%) respectively. Among side effects reported 
as reasons for hospitalization anemia (25%), febrile neutropenia (21%) and fatigue 
(20%) were most frequently reported. ConClusions: Burden of hospitalization in 
advanced lung cancer patients is significant in the United States. Innovative thera-
pies with favorable side effect profile that also alleviate need for surgery and are 
effective in improving lung cancer symptoms could help significantly in decreasing 
hospitalization burden in advanced lung cancer patients.
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of oNCologIsTs IN euroPeaN uNIoN, uNITeD sTaTes, ChINa aND brazIl
Narayanan S.
Ipsos Healthcare, Gaithersburg, MD, USA
objeCtives: To assess oncologist perception of their country-specific health care 
reforms and the consideration of ‘Real World Evidence’ (RWE) when prescribing 
medications in the EU, US, China and Brazil. Methods: A multi-country cross-
sectional survey was conducted in top-5 EU countries (UK, Germany, Spain, France, 
Italy), US, Brazil and China in February 2013 using an online physician panel in the 
respective geographies; oncologists were randomly selected for survey participation 
to be geographically representative in each country. Surveys assessed the oncologist 
perceptions of health care reforms in their respective countries, and their considera-
tion of the following, when prescribing oncology medications: RWE on product effec-
tiveness/safety, patient quality-of-life (QoL) and product cost/patient affordability. 
Descriptive statistics are reported. Results: A total of 257 oncologists participated 
in the survey. Specialties included: medical oncology-69%, haemato-oncology-11%, 
radiation-oncology-9%, surgical-oncology-5%, gynecologic-oncology-3%, pediat-
ric-oncology-2%, other-2%. Geographic distribution of oncologists was: 5EU-36%, 
US-33%, China-17% and Brazil-14%. Overall, 40% of oncologists indicated that 
they were ‘not sure whether their country’s health care reform is heading in the 
right direction’ (5EU:39%, US:40%, China:44%, Brazil:36%); 38% indicated that they 
were ‘concerned of country’s health care reform’s implications for them and their 
practice’ (5EU:30%, US:50%, China:44%, Brazil:19%); 23% indicated that the health 
care reform ‘did not have enough focus on RWE needs and cost-effectiveness of 
medications’ ((5EU:16%, US:24%, China:37%, Brazil:19%). When prescribing oncology 
medications, consideration of following attributes ‘all the time’ differed across the 
countries (Overall/5EU/US/China/Brazil): RWE on product effectiveness and safety 
(37%/29%/38%/47%/42%), patient QoL (54%/48%/59%/42%/69%), product cost/patient 
affordability (23%/15%/20%/42%/28%). ConClusions: Across markets, a significant 
proportion of oncologists raised concerns regarding their country-specific health 
care-reforms, and between one-third and half of the oncologists reported consid-
ering RWE data while prescribing medicines. As the health care reforms evolve in 
the studied countries, its actual implications warrant closer scrutiny to alleviate 
physician concerns and improve care delivery and outcomes.
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objeCtives: Research has shown that circulating tumor cells (CTCs) in the blood 
can give valuable information about the prognosis and treatment options in oncol-
ogy. A new approach, CTC therapeutic apheresis (CTCtrap) is being developed for use 
in breast and prostate cancer. At the moment it is not clear where in the diagnostic 
track CTCtrap could be of most value. The goal of this study is to estimate the health 
impact of using CTCtrap in 1) screening for breast cancer; 2) early staging of tumors; 
and 3) therapy response monitoring. Methods: A systematic literature study and 
experts’ interviews were used to document the diagnostic track in breast cancer. 
Headroom analysis and early health economic modelling was used to estimate the 
health impact of implementing CTCtrap at the three different purposes. Results: 
Dependent on the assumption of sensitivity, the CTCtrap could decrease the total 
screening costs. Yet, it is expected that this application only has limited clinical util-
ity. In the early staging, the CTC trap can replace the currently used FDG-PET-CT. The 
CTCtrap could provide additional staging information and therapy can be selected 
more specifically, eliminating unnecessary costs. Finally, CTCtrap as a monitoring 
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initial analysis of the first 18 months of the SPA scheme indicated that the length of 
gefitinib therapy was at least that anticipated by NICE. This study aims to validate 
the length of therapy in a larger cohort with up to 3 years follow-up. Methods: The 
SPA administrative database contained information on packs (30-days therapy/pack) 
dispensed to patients from September 2009 to December 2012. This retrospective 
study included patients registered on the database prior to the end of 2012, fulfill-
ing NICE eligibility criteria and receiving at least 3 packs for which the NHS was 
invoiced. Patients were considered censored if they had ≥ 1 pack recorded in the last 
3 months of the database. Median time to treatment cessation was estimated from 
a Kaplan-Meier curve of packs supplied to patients and the mean number of packs 
dispensed per patients from a parametric failure time model. Results: 883/1160 
registered patients met the study eligibility criteria (460/883 censored). These 883 
patients, for whom the NHS was invoiced the single fixed payment, received a median 
of 13 packs 95%CI[12,14], equivalent to 12.8 months to treatment cessation. A mean of 
19.4 95%CI[18.0, 21.0] packs were dispensed per patient. ConClusions: The results 
of this observational study confirm the average length of gefitinib therapy and mean 
number of packs dispensed in the SPA scheme exceed that assumed by NICE.
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TreaTmeNT PaTTerNs of INDoleNT NoN-hoDgkIN lymPhoma PaTIeNTs 
uNDer The brazIlIaN PublIC healTh Care PersPeCTIve
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objeCtives: To identify the chemotherapeutic treatment patterns in patients with 
indolent non-hodgkin lymphoma (NHL) treated in the Brazilian Public Healthcare 
System. Methods: A retrospective longitudinal analysis based on the Government 
administrative claims database (Datasus) was performed from January 2008 to 
December 2012. Eligibility criteria were patients with indolent NHL diagnosed until 
January 2012 and starting their first chemotherapy regimen from January 2008 to 
January 2012. This cohort of patients was followed until December 2012, death or loss 
of follow-up. Patients without interruption during treatment and without change in 
medication were considered in the same chemotherapy regimen. Descriptive statis-
tics (average, standard deviation and percentage) of treatment regimens, treatment 
free interval (TFI), age at the beginning of treatment, gender and length of treatment 
were performed. Results: A total of 817 patients with indolent NHL representing 
5,449 APACs (Authorization for High Complexity Procedures) met eligibility criteria. 
The population cohort comprised 50.7% men with an average age of 61.3±14.5years. 
72.2% of the patients had only one chemotherapy regimen, whereas 18.2% had two 
and 9.1% had three or more chemotherapy regimens. Time between diagnose and 
the beginning of treatment was 3.6±6.2 months. The most widely used first chemo-
therapy regimen was cyclophosphamide, vincristine and prednisolone (CVP)(22.2%) 
followed by cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) 
and rituximab(15.7%), cyclophosphamide, vincristine and prednisolone (COP) and 
rituximab(5.6%), chlorambucil and prednisone(4.8%). Average length of treatment 
was 5.0±3.7months. For second chemotherapy scheme, the most widely used regi-
men was CHOP and rituximab(14.1%), CVP(7.5%), interferon(9.3%), chlorambucil 
and prednisone(6.2%). The average length of treatment was 4.0±4.1months, with 
an average TFI of 3.3±4.2months. ConClusions: The most used chemotherapy in 
first regimen was CVP. Rituximab in combinations was present in most patients in 
the first scheme. Rituximab in second scheme in combination with CHOP was the 
most used therapy. The length of treatment was longer in first scheme.
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CurreNT sITuaTIoN of oral aNTICaNCer TreaTmeNTs use IN fraNCe: 
The aCTor sTuDy (aNalysIs of CaNCer TreaTmeNTs gIveN orally)
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objeCtives: Within the last decade market authorizations for oral anticancer treat-
ments (OATs) have increased. This analysis aimed at describing the current situ-
ation of OATs and their modalities of use. Methods: An analysis was performed 
from Oncology Analyzer™ (IMS Health, France), a physician survey database covering 
more than 10,000 cancer patients per year treated in both public and private insti-
tutions from multiple French regions. The database includes patient demograph-
ics, diagnosis and treatment patterns. Data was extracted for all types of cancers 
and described as number of patients treated by oral and intravenous (IV) anticancer 
drugs. Data was collected from October 2011 to September 2012. Analyses were split 
into different active anticancer treatment categories and excluded supportive care 
agents. Results: A total of 7426 patients treated with oral and IV anticancer treat-
ments in France were included in the analysis. The male/female ratio was 47%/53% 
and 58% of patients were aged over 60 years old. Patients receiving OATs were mainly 
diagnosed with a solid tumor (74%) such as breast cancer (34%), non-small cell lung 
cancer (8%) and colorectal cancer (7%). OATs represented 45% (54/119) of all molecules 
available (oral and IV) of which 44% (24/54) were cytotoxic chemotherapies, 28% (15/54) 
were targeted therapies, 22% (12/54) were hormonal-therapies and 6% (3/54) were 
immunotherapies. 32% of patients (2,410/7,426) received a regimen containing at least 
one OATs among them 78% received OATs only versus 18% received a combination 
of oral and IV drug. Sixty-one percent of patients aged over 80 years received OATs, 
as compared to 26% of patients aged less than 60 years. ConClusions: The ACTOR 
study is the first analysis focused on the understanding of the pattern of use of OATs. 
One third of cancer patients in France are treated with OATs especially among the 
elderly. Further research is needed to understand the OATs uptake.
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11 SMC; 9 PBAC; 3 TLV; 4 pCODR; 3 INESS. The literature search revealed the follow-
ing WTP-ICERs: NICE (20,000 - 30,000 GBP); SMC (30,000 GBP); PBAC (45,000 – 75,000 
AUD); TLV (777,000 SEK); pCODR and INESS (50,000 – 70,000 CAD). Of the agencies 
with specific EOL policies, the number of drugs recommended as cost-effective 
despite final ICERs greater than the respective WTP-ICERs were 11 (65%) NICE; 5 
(45%) SMC; 0 PBAC and 1 (33%) INESSS. The corresponding figures for the agencies 
with no specific EOL policy were 0 TLV and 4 (100%) pCODR. ConClusions: The 
evidence suggests some HTA bodies treat EOL conditions differently, however the 
example of pCODR suggests this need not depend on having a specific EOL policy. 
In fact, the results for PBAC and INESSS show that having a specific EOL policy is 
no guarantee EOL conditions are treated differently.
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objeCtives: To identify the chemotherapeutic treatment patterns in patients 
with chronic lymphocytic leukemia (CLL) treated in the Brazilian Public Healthcare 
System. Methods: A retrospective longitudinal analysis based on Government 
administrative claims database (Datasus) was performed from January 2008 to 
December 2012. Eligibility criteria were patients with CLL (ICD code C911) diagnosed 
until January 2012 and starting their first chemotherapy regimen from January 2008 
to January 2012. This cohort of patients was followed until December 2012, death or 
loss of follow-up. Patients without interruption during treatment and without change 
in medication were considered in the same chemotherapy regimen. Descriptive sta-
tistics (average, standard deviation and percentage) of treatment regimens, treat-
ment free interval (TFI), age at treatment start, gender and length of treatment were 
performed. Results: A total of 1,538 patients with CLL representing 15,371 APACs 
(Authorization for High Complexity Procedures) met eligibility criteria. The popula-
tion cohort comprised 56.6% men with an average age of 67.4±12.1 years. 55.0% of 
the patients had only one chemotherapy regimen, whereas 44.9% had two and 19.4% 
had three or more chemotherapy regimens. Time between diagnosis and beginning 
of treatment was 4.3±7.6 months. The most widely used first chemotherapy regimen 
was chlorambucil (54.9%), followed by cyclophosphamide, vincristine and predni-
solone (CVP) (9.1%), fludarabine and cyclophosfamide (FC) (8.1%) and chlorambucil 
and prednisone (7.0%). Average length of treatment was 6.3±5.7 months. For second 
chemotherapy scheme, the most widely used regimen was chlorambucil (45.3%), fol-
lowed by FC (11.0%), CVP (7.8%), chlorambucil and prednisone (6.2%) and CHOP (3.5%). 
The average length of treatment was 4.9±3.6 months, with an average TFI of 3.5±5.0 
months. ConClusions: Chlorambucil was the most used therapy as both first and 
second chemotherapy regimen. There was a decreasing of Chlorambucil and an 
increasing of FC in second scheme. The length of treatment was longer in first scheme.
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objeCtives: Within the last decade market authorizations for oral anticancer 
treatments (OATs) have increased but no published data are available on their 
use over time. This analysis aimed at describing the evolution of OATs use in 
France. Methods: A retrospective analysis was performed from Oncology Analyzer™ 
(IMS Health, France), a physician survey database covering more than 10,000 cancer 
patients per year treated in both public and private institutions from multiple French 
regions. The database includes patient demographics, diagnosis and treatment pat-
terns. Data were extracted for all cancers patients treated by oral and intravenous 
(IV) anticancer drugs from October 2004 to September 2012. Analyses included active 
anticancer treatments (chemotherapy, targeted therapy, hormonal-therapy, immu-
notherapy) excluding supportive care agents. Results: The proportion of cancer 
patients receiving OATs increased from 2,241/7,891 (28%) to 2,410/7,426 (32%). Data 
showed an increasing use of OATs over time especially among patients aged over 70 
years (i.e. 40% in 2004 vs. 46% for patients in 2012). The proportion of OATs among all 
anticancer drugs (oral and IV) remains stable over time (45.1% in 2005 (41/91) vs. 45.4% 
in 2012 (54/119). The number of molecules available in oral form was stable except for 
targeted therapies (4 in 2004 vs. 15 in 2012). Data related to some molecules available 
in both forms (oral and IV) such as melphalan, fludarabine, topotecan, confirmed 
the preferential use for the oral route of administration over time. ConClusions: 
The Re-ACTOR study confirms the increasing uptake of OATs in oncology in France. 
The number of patients receiving OATs increases over time especially for targeted 
therapies. This trend draws the attention of the necessity to reinforce measures to 
accompany the development of OATs in terms of safety and health care delivery, 
especially for the elderly who require specific attention to provide them with patient 
support tools and programs.
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Three years of The gefITINIb uk sINgle PaTIeNT aCCess (sPa) sCheme: 
DuraTIoN of TreaTmeNT for PaTIeNTs wITh egfr muTaTIoN PosITIve 
NsClC IN Nhs ClINICal PraCTICe
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objeCtives: The UK National Institute for Health and Clinical Excellence (NICE) 
recommended gefitinib as cost-effective for use first line in locally advanced or 
metastatic, EGFR mutation positive NSCLC, when supplied via the SPA scheme, 
based on the mean duration of treatment observed in the IPASS study (8.8 months). 
The single fixed payment under the scheme is triggered at the order of the third 
30-day pack and covers a patient for their total supply of gefitinib treatment. An 
